D-1040-2019 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-1040-2019 was initiated by Macleods Pharma Usa Inc on Feb 21, 2019 and is designated Class II. Reason for recall: CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient. The recall status is terminated (terminated Sep 28, 2020). Affected quantity: 9695 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2019
Initiation Date
Feb 21, 2019
Termination Date
Sep 28, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9695 bottles

Product description

Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 90 count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-0052-10

Reason for recall

CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.

Distribution pattern

NJ, NY, FL

Code information

Lot BLM715A, Jul-19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1040-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1040-2019. Report a data issue: hello@regdatalab.com.